Amneal Pharmaceuticals, Inc.
AMRX
$10.48
$0.121.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.85B | 2.83B | 2.79B | 2.68B | 2.60B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.85B | 2.83B | 2.79B | 2.68B | 2.60B |
| Cost of Revenue | 1.79B | 1.80B | 1.78B | 1.70B | 1.65B |
| Gross Profit | 1.07B | 1.03B | 1.02B | 979.05M | 943.11M |
| SG&A Expenses | 489.93M | 482.13M | 476.44M | 456.75M | 451.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -5.12M | -5.12M | 100.00K | 100.00K | 173.00K |
| Total Operating Expenses | 2.47B | 2.47B | 2.45B | 2.34B | 2.27B |
| Operating Income | 379.72M | 364.10M | 348.26M | 339.67M | 329.06M |
| Income Before Tax | 89.30M | 58.00M | -55.01M | -123.16M | -115.62M |
| Income Tax Expenses | 38.06M | 25.58M | 18.86M | 23.32M | 17.58M |
| Earnings from Continuing Operations | 51.24 | 32.42 | -73.88 | -146.48 | -133.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -47.87M | -45.47M | -43.01M | -37.98M | -41.41M |
| Net Income | 3.38M | -13.05M | -116.89M | -184.45M | -174.62M |
| EBIT | 379.72M | 364.10M | 348.26M | 339.67M | 329.06M |
| EBITDA | 625.08M | 604.92M | 584.45M | 566.66M | 554.29M |
| EPS Basic | 0.01 | -0.04 | -0.38 | -0.68 | -0.62 |
| Normalized Basic EPS | 0.02 | -0.05 | -0.07 | 0.01 | 0.02 |
| EPS Diluted | 0.01 | -0.04 | -0.38 | -0.69 | -0.63 |
| Normalized Diluted EPS | 0.01 | -0.05 | -0.07 | 0.01 | 0.02 |
| Average Basic Shares Outstanding | 1.24B | 1.24B | 1.24B | 1.17B | 1.01B |
| Average Diluted Shares Outstanding | 1.27B | 1.26B | 1.25B | 1.18B | 1.03B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |